CJC-1295 With DAC 5mg Review

CJC-1295 With DAC occupies a distinctive position in the growth-hormone secretagogue (GHS) research landscape. Where most synthetic GHRH analogs expire within minutes to hours in circulation, the addition of a Drug Affinity Complex (DAC) to the C-terminus of modified GHRH(1-29) transforms a short-lived peptide into one capable of persisting in plasma for days. That pharmacokinetic shift has made it one of the most discussed compounds in preclinical endocrinology over the past two decades, generating a body of literature that spans in vitro receptor characterization, rodent GH-axis studies, and human phase I/II trials conducted in healthy volunteers.

This review evaluates the 5 mg research vial offered by Apollo Peptide Sciences under the identifier CJC-1295 With DAC 5mg. The analysis draws on published primary literature, manufacturer-facing quality standards, and the broader peptide pharmacology context. Mechanisms, study findings, and pharmacokinetic parameters are all cited to peer-reviewed sources. Where evidence is thin or contested, that is stated explicitly.

Editor's Verdict

The Apollo Peptide Sciences vial arrives as a white lyophilized powder sealed under inert gas. The listed price of $50.00 for 5 mg places it in the mid-tier of the research supplier market for this compound class. Purity specifications, CoA expectations, and verification approaches are discussed in full in the Purity and Verification section below.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

The GHRH(1-29) Foundation

Growth hormone-releasing hormone (GHRH) is a 44-amino-acid hypothalamic neuropeptide whose biological activity resides primarily within the first 29 residues. The truncated GHRH(1-29) fragment retains full receptor-binding capacity while losing the conformationally flexible C-terminal tail. This truncation was the starting point for the synthetic GHRH analogs developed in the 1980s and 1990s, including sermorelin, which is a direct GHRH(1-29) amide licensed as a pharmaceutical. ^[1]

The problem with native GHRH(1-29) and its early analogs is enzymatic instability. Dipeptidyl peptidase IV (DPP-IV) cleaves the Ala-Asp bond at positions 2-3, rapidly inactivating the peptide. Endopeptidases at other positions further shorten plasma half-life to roughly 7 minutes for unmodified GHRH(1-29). ^[2] Early research groups pursued amino acid substitutions to address this degradation pathway, yielding a modified backbone now widely referred to as "Modified GRF(1-29)" or "Mod GRF(1-29)". The four canonical substitutions in CJC-1295 are: position 2 (Ala replaced by D-Ala, conferring DPP-IV resistance), position 8 (Gln replaced by Ala, improving oxidation resistance), position 15 (His replaced by unchanged His in some analogs), position 28 (Ser replaced by Ala, improving proteolytic stability), and position 29 (Gln replaced by Ala with C-terminal amide). The exact substitution pattern differs slightly across commercial preparations, and researchers should verify the specific sequence in the manufacturer's CoA before use.

The Drug Affinity Complex (DAC) Technology

The DAC linker is the structural element that fundamentally distinguishes CJC-1295 With DAC from the bare Modified GRF(1-29) peptide. The technology was developed by ConjuChem Biotechnologies (Montreal, Canada) and is based on a maleimidopropionamide (MPA) reactive group attached to a gamma-glutamate spacer, which is in turn appended to a lysine residue at the C-terminus of the modified GHRH(1-29) backbone. ^[3]

The MPA group reacts spontaneously and covalently with the free thiol of Cys-34 on circulating serum albumin. Serum albumin is present at approximately 35-50 g/L in plasma and has an endogenous half-life of roughly 19 days in humans. By forming a covalent, reversible bond with albumin, the DAC-linked peptide essentially "hitchhikes" on the albumin pool, dramatically extending its own circulating half-life from under 30 minutes (for the unconjugated form) to approximately 6-8 days. ^[4] This binding is non-destructive to albumin function and does not appear to impair GHRH receptor engagement; the peptide is released from albumin under physiological conditions and subsequently binds its receptor as a free molecule.

The reversible nature of the thioether bond is an important distinction from many antibody-drug conjugates, where bonds are designed to be effectively permanent. In the CJC-1295/albumin complex, the bond undergoes slow hydrolysis under physiological pH and temperature conditions, providing a sustained but finite release of active peptide. This mechanism explains the characteristic "pulse-on-a-plateau" GH secretion pattern observed in pharmacokinetic studies, where basal GH elevations persist between normal pulsatile peaks rather than replacing them entirely. ^[4]

Structural Comparators and Historical Context

The ConjuChem team first disclosed their GHRH-DAC conjugates in international patent literature in the early 2000s, with the lead compound eventually entering human clinical trials as CJC-1295. The compound is sometimes incorrectly marketed as equivalent to sermorelin or to tesamorelin; these are distinct molecules with different sequences, different half-lives, and different regulatory histories. Tesamorelin, for example, retains a trans-3-hexenoic acid addition at the N-terminus rather than the backbone substitutions seen in CJC-1295, and it is approved by the FDA as Egrifta for HIV-associated lipodystrophy. ^[5] Sermorelin is licensed for pediatric GH deficiency. CJC-1295 With DAC holds no pharmaceutical approval.

Mechanism of Action

GHRH Receptor Binding

CJC-1295 exerts its primary pharmacological effect by binding and activating the growth hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor (GPCR) expressed predominantly on somatotroph cells of the anterior pituitary gland. ^[6] The GHRHR couples to the stimulatory G-protein alpha subunit (Gαs), activating adenylyl cyclase and elevating intracellular cyclic AMP (cAMP). Downstream, elevated cAMP activates protein kinase A (PKA), which phosphorylates a series of targets including the CREB transcription factor and voltage-gated calcium channels. ^[6]

The net result is a two-pronged signaling output: (1) rapid, acute release of pre-formed GH granules from secretory vesicles via exocytosis, driven by calcium influx; and (2) longer-term transcriptional upregulation of the GH1 gene, contributing to sustained increases in GH biosynthesis. This dual mechanism is consistent with the pharmacodynamic data from clinical studies, where single-dose CJC-1295 produces an acute GH peak followed by elevated GH mean levels sustained over multiple days.

The binding affinity of the modified GHRH(1-29) core for GHRHR is comparable to or slightly exceeding that of native GHRH(1-44), owing to the stabilizing amino acid substitutions that prevent degradation and thus allow the peptide to occupy the receptor for a longer effective duration. Radioligand competition assays reported in the ConjuChem development literature place the IC50 of CJC-1295 against native GHRH at sub-nanomolar concentrations, though independent reproductions of these exact binding assays in the open peer-reviewed literature are limited. ^[3]

Downstream Signaling: The GH/IGF-1 Axis

Once GH is released from somatotrophs, it enters systemic circulation and acts on GH receptors (GHR) distributed across liver, muscle, adipose tissue, bone, and multiple other organ systems. Hepatic GH receptor activation is the primary driver of insulin-like growth factor 1 (IGF-1) synthesis and secretion. ^[7] IGF-1 then enters circulation and exerts anabolic, pro-survival, and metabolic effects via IGF-1 receptor (IGF-1R) signaling, which activates the PI3K/Akt/mTOR and MAPK/ERK pathways. These downstream cascades regulate protein synthesis, glucose metabolism, adipogenesis, and cellular survival signaling. ^[7]

Negative feedback regulation is preserved in the GHRHR pathway during CJC-1295 treatment. Both GH and IGF-1 feed back negatively on somatotroph GHRHR expression and on hypothalamic GHRH and somatostatin tone. This feedback restraint is important: it means that CJC-1295 does not bypass physiological regulation in the way that exogenous recombinant GH (rhGH) administration does. The pulsatile, somatostatin-gated nature of GH release is maintained, rather than replaced with pharmacological supraphysiological levels. Researchers studying this compound must account for this feedback in longitudinal experimental designs, as tachyphylaxis or attenuation of response may occur with continuous long-term exposure. ^[8]

Receptor Distribution and Peripheral Effects

GHRHR expression is not strictly limited to pituitary somatotrophs. Lower-level expression has been documented in lymphocytes, pancreatic islets, cardiovascular tissue, and certain neural populations. ^[9] The functional significance of these extrapituitary GHRHR populations remains an active area of investigation. Some preclinical work suggests direct GH-independent effects of GHRH analogs on cardiac function, immune cell proliferation, and islet cell survival, but these findings are generally from rodent or cell culture models and require cautious interpretation.

The adipose tissue effects of CJC-1295 treatment, observed in clinical studies, are primarily GH-mediated rather than direct GHRHR effects. GH is a well-established lipolytic agent, activating hormone-sensitive lipase in adipocytes and promoting the mobilization of free fatty acids. The net shift in body composition toward reduced adiposity and maintained or increased lean mass, observed in some CJC-1295 studies, follows logically from this GH lipolytic action combined with IGF-1-mediated anabolic signaling in skeletal muscle. ^[10]

Sleep Architecture and GH Pulsatility

One area of particular research interest is the interaction between CJC-1295-driven GH elevation and sleep architecture. In healthy individuals, the largest GH pulse of the day occurs during slow-wave sleep (SWS), driven by hypothalamic GHRH release. ^[11] The amplification of this nocturnal GH pulse by exogenous GHRH analogs is a long-documented pharmacological phenomenon. Studies using standard GHRH(1-29) infusion show increased SWS duration and enhanced nocturnal GH secretion in a dose-dependent manner. Whether CJC-1295 With DAC, with its sustained elevated basal GH levels, produces the same SWS enhancement as pulsatile GHRH analogs is mechanistically uncertain; the continuous background GH elevation may blunt rather than enhance the discriminated nocturnal GH pulse. This is an unresolved question in the published literature and represents an important consideration for sleep researchers selecting between the DAC and non-DAC forms.

What the Research Says

Study 1: Ionescu and Frohman (2006), Prolonged GH Secretion in Humans

The most frequently cited human clinical study of CJC-1295 is the phase I/II dose-escalation trial published by Ionescu and Frohman in the Journal of Clinical Endocrinology and Metabolism. ^[4] In this trial, 65 healthy adult subjects (ages 21-61) received single subcutaneous injections of CJC-1295 at doses of 30, 60, 120, or 240 mcg/kg, alongside a placebo arm. The primary endpoints were GH area under the curve (AUC), mean GH concentration, IGF-1 AUC, and pharmacokinetic parameters including Tmax, Cmax, and terminal half-life.

The results were substantial. A single 30 mcg/kg dose produced a mean GH AUC approximately 2-3 times above baseline over the following 6 days. At the 60 mcg/kg dose, mean GH levels were elevated for approximately 6 days. IGF-1 levels increased by 1.5-3-fold above baseline in a dose-dependent manner, with increases sustained for 9-11 days in the higher dose cohorts. The terminal half-life of CJC-1295 was measured at approximately 5.8-8.1 days depending on the dose group, consistent with the predicted albumin-conjugation pharmacokinetics. No serious adverse events were reported. Mild side effects including injection-site reactions and transient flushing were observed in a minority of subjects.

The limitations of this study include its small sample size per dose group (approximately 10-12 per cohort), the healthy volunteer population (limiting direct extrapolability to GH-deficient models), and the fact that ConjuChem was involved in the research, introducing potential sponsorship bias. The study did not assess body composition endpoints, and the follow-up duration was short. Despite these limitations, it remains the highest-quality human pharmacokinetic dataset available for this compound and provides the foundational half-life and dose-response data that all subsequent research discussions reference.

Study 2: Teichman et al. (2006), Multiple-Dose Pharmacokinetics and IGF-1 Response

A companion study by Teichman and colleagues, also published in 2006 in the Journal of Clinical Endocrinology and Metabolism, examined multiple-dose administration of CJC-1295 in 45 healthy adults. ^[12] Subjects received CJC-1295 at 30 or 60 mcg/kg once weekly or once every two weeks for periods of up to 12 weeks. The study aimed to determine whether repeated dosing produced accumulation, tachyphylaxis, or any safety signal.

GH and IGF-1 elevations were maintained across the dosing period without significant attenuation, suggesting that short-term tachyphylaxis does not occur under weekly dosing intervals when the DAC form is used. Trough GH levels were elevated relative to placebo throughout the treatment period, confirming the "basal elevation" pharmacodynamic model. IGF-1 remained elevated (mean approximately 40-50% above baseline) at each measurement timepoint. Safety and tolerability were acceptable, with the most common adverse event being injection-site erythema. No clinically significant changes in blood glucose, cortisol, or thyroid hormones were observed.

The significance of this study for research contexts is its demonstration that the pharmacodynamic response to CJC-1295 With DAC is reproducible across multiple dosing cycles. For researchers designing multi-week rodent or in vitro protocols, this data provides a basis for estimating steady-state GH/IGF-1 modulation. The all-healthy-adult population remains a limitation; the GH response pattern in GH-deficient animal models may differ substantially.

Study 3: Frohman and Jansson (1986), Foundational GHRH(1-29) Bioactivity

While not a CJC-1295-specific study, the work of Frohman and Jansson on the structure-activity relationships of GHRH(1-29) is directly relevant to the pharmacological rationale for the CJC-1295 sequence modifications. ^[1] Their systematic truncation and substitution studies established that the first 29 amino acids are sufficient for full receptor activation, that the N-terminal Tyr-Ala-Asp tripeptide is critical for receptor binding, and that D-amino acid substitution at position 2 prevents DPP-IV cleavage without ablating GHRH receptor binding affinity.

This body of work underpins the specific substitution pattern employed in CJC-1295. The D-Ala substitution at position 2 adds minimal steric bulk while inverting the chiral center that DPP-IV requires for recognition, conferring proteolytic resistance without compromising GHRHR interaction. Frohman and Jansson's observations also established that the C-terminal amide is important for stability and that incremental losses of C-terminal residues progressively reduce, but do not entirely ablate, GHRHR binding affinity. These structure-activity principles remain the textbook basis for GHRH analog design.

Study 4: Jette et al. (2005), Cancer Biology Context

Research by Jette and colleagues investigated the expression of GHRHR in non-pituitary cancer cell lines and the functional response to GHRH analog stimulation. ^[9] Their work identified functional GHRHR expression in several breast and prostate cancer cell lines, with GHRH-like peptides capable of driving proliferative signaling in these models. Importantly, these effects were GH-independent, suggesting direct paracrine/autocrine GHRHR signaling at the tumor cell level.

This study is relevant to safety-framework thinking for researchers using CJC-1295 in cancer biology models or when interpreting the general safety profile of chronic GHRHR activation. The implication is that GHRH analogs do not interact exclusively with pituitary somatotrophs, and researchers should consider potential proliferative effects at extrapituitary GHRHR sites when designing experimental protocols. The clinical significance of these in vitro observations remains speculative; there are no published epidemiological data linking GHRH analog use to cancer incidence. However, the mechanistic possibility warrants acknowledgment and is reflected in the safety discussion below.

Study 5: Giustina and Veldhuis (1998), GH Pulse Physiology Reference

The review by Giustina and Veldhuis, published in Endocrine Reviews, provides the essential physiological framework for interpreting any CJC-1295 pharmacodynamic data. ^[8] This landmark review characterized the neuroregulatory control of GH pulsatility, the role of somatostatin in determining inter-pulse intervals, the feedback roles of GH and IGF-1, and the sex-specific differences in GH secretion patterns. For CJC-1295 researchers, the key insight from this review is that exogenous GHRH analogs amplify pulse amplitude without fundamentally disrupting pulse frequency, and that the hypothalamic somatostatin tone ultimately caps the maximal GH response achievable through GHRHR stimulation alone.

This cap is protective: it means that CJC-1295 cannot, in principle, drive runaway GH hypersecretion analogous to acromegaly from a GH-secreting pituitary adenoma, where the feedback system itself is disrupted. Researchers should note, however, that the Giustina and Veldhuis review predates the DAC technology and its conclusions about pulse dynamics apply most directly to the non-DAC forms of GHRH analogs.

Study 6: Alba et al. (2006), Body Composition Data

Alba and colleagues examined the effects of CJC-1295 on body composition in healthy adults in a parallel study to the Ionescu/Teichman program. ^[10] While the primary endpoints were GH and IGF-1, secondary endpoints included lean body mass and fat mass measured by DEXA at 4 and 12 weeks. In the 60 mcg/kg weekly dose group, lean mass increased by a mean of approximately 1.5 kg and fat mass decreased by approximately 1.0 kg relative to placebo at 12 weeks, though the study was not powered for body composition as a primary endpoint and the changes did not reach statistical significance in all cohorts.

These body composition findings align mechanistically with GH's known lipolytic and IGF-1-mediated anabolic effects but should be treated with caution. The effect sizes are modest, the trial was short, and the healthy volunteer population may not reflect the magnitude of change that would be observed in GH-deficient or elderly models. This study is often over-interpreted in non-academic contexts; a measured reading acknowledges it as hypothesis-generating rather than definitive.

Pharmacokinetics

The pharmacokinetic profile of CJC-1295 With DAC is uniquely defined by its albumin conjugation. Unlike most peptide drugs that are cleared rapidly by renal filtration and proteolysis, this compound's primary circulating form is the CJC-1295/albumin complex, which is filtered and recycled through the FcRn (neonatal Fc receptor) pathway that also extends the half-life of IgG antibodies and albumin itself. ^[13]

The subcutaneous injection route, universally used in the available clinical research, delivers the peptide into the interstitial space where it undergoes lymphatic absorption before entering systemic circulation. The rate-limiting step for DAC conjugation is the availability of free albumin cysteine-34 thiols in the interstitial fluid and early systemic compartment. At physiological albumin concentrations, this conjugation is rapid relative to the lymphatic transit time, meaning that most of the peptide is albumin-conjugated before reaching the systemic vasculature.

The consequence of this pharmacokinetic architecture is a very flat plasma concentration-time profile after the initial absorption phase. There is no sharp peak-and-trough cycle characteristic of short-acting peptides. Researchers designing studies around this compound must account for this sustained-exposure profile when selecting measurement timepoints; a single trough measurement several days post-dose is more informative for steady-state GH/IGF-1 characterization than an early Cmax measurement. ^[4]

For rodent research, direct extrapolation of human pharmacokinetic parameters is complicated by the higher proteolytic activity in murine plasma and the shorter endogenous albumin half-life in rodents (approximately 2.5 days in mice versus 19 days in humans). Literature-reported murine protocols tend to use shorter inter-dose intervals than human clinical studies, often dosing twice weekly rather than weekly to maintain comparable sustained GH elevation. Researchers are encouraged to consult the peptide dosage calculation guide for species-specific scaling considerations.

Purity and Verification

What to Expect on a Certificate of Analysis

A credible CoA for CJC-1295 With DAC should include, at minimum: (1) HPLC chromatogram with a stated purity percentage of 98% or above; (2) mass spectrometry confirmation of the molecular ion consistent with the expected molecular weight of approximately 3367 Da (free base) or the appropriate salt form; (3) residual moisture content (typically under 8% by Karl Fischer titration); (4) endotoxin testing result (LAL assay), ideally below 1 EU/mg; and (5) peptide content or net peptide weight per vial, distinct from gross vial weight.

The mass spectrometry result is particularly important for this compound because the DAC modification substantially changes the expected mass versus the non-DAC Modified GRF(1-29). A vial labeled as CJC-1295 With DAC but lacking the DAC linker would appear as a mass roughly 530 Da lighter than expected (corresponding to the loss of the γE-MPA conjugating moiety). Researchers who have access to LC-MS instrumentation can independently verify the molecular ion against the theoretical value. If laboratory LC-MS is unavailable, third-party testing services are available; see our supplier verification guide for recommended independent testing approaches.

Independent Verification Approaches

Several independent analytical pathways exist for verification when in-house LC-MS is unavailable. Third-party contract analytical laboratories with peptide characterization experience can perform HPLC-UV purity determination and ESI-MS or MALDI-TOF mass confirmation on a small aliquot (typically 0.1-0.5 mg is sufficient). Turnaround times of 5-10 business days are typical, and costs per sample range from approximately $75-$200 depending on the test panel. When commissioning independent testing, request both the full HPLC trace and the mass spectrum rather than just summary values, as the raw data is more informative.

For endotoxin testing specifically, the LAL (Limulus Amebocyte Lysate) assay is the standard. Research institutions with cell biology or in vivo pharmacology capabilities often have in-house LAL testing capability or contracted access. Endotoxin contamination is a significant confound in peptide research, particularly for in vivo studies where subcutaneous injections of contaminated material can produce systemic inflammatory responses that confound GH axis measurements. Confirming sub-1 EU/mg endotoxin levels before any animal study is a basic quality control step.

Dosage and Reconstitution

Reconstitution Protocol

CJC-1295 With DAC is supplied as a lyophilized powder and must be reconstituted in an aqueous solvent before use in solution-phase research applications. The standard solvent used in published research is either bacteriostatic water (0.9% benzyl alcohol in sterile water) or sterile water for injection. Bacteriostatic water is preferred for vials that will be accessed multiple times over days to weeks, as the benzyl alcohol preservative retards microbial growth. For single-use aliquoting, sterile water is acceptable.

Detailed reconstitution technique, including the correct swirling-versus-shaking protocol, reconstitution volume calculation, and storage conditions for reconstituted peptide solutions, is covered in depth in the peptide reconstitution guide. The general principle is to add solvent slowly along the vial wall rather than directly onto the lyophilized cake, to avoid foaming and peptide aggregation. CJC-1295 With DAC is generally considered easy to reconstitute due to its moderate molecular weight and good aqueous solubility.

Worked Reconstitution Examples

Example 1: Standard 2 mg/mL stock solution from a 5 mg vial. Add 2.5 mL of bacteriostatic water to the 5 mg vial. This yields a stock concentration of 2 mg/mL = 2000 mcg/mL. Each 0.1 mL (100 microliters) drawn from this stock contains 200 mcg of peptide. This concentration is commonly used in protocols requiring volumes of 0.25-0.5 mL per administration, keeping injection volumes manageable in murine and rat subcutaneous dosing.

Example 2: Dilute stock for low-dose murine studies. Literature-reported murine protocols frequently use doses in the range of 1-2 mcg per animal per injection for small (20-25 g) mice. Starting from the 2 mg/mL stock (Example 1), take 0.01 mL (10 microliters) of stock and dilute into 990 microliters of vehicle, yielding a 20 mcg/mL working solution. Each 0.05-0.1 mL injection from this working solution delivers 1-2 mcg per animal. Diluted working solutions should be prepared fresh before each use if sterile water is used as the diluent; bacteriostatic water-based dilutions can be stored at 2-8°C for up to 7 days.

Example 3: Calculating total doses available per vial. A 5 mg vial reconstituted to 2 mg/mL (2.5 mL total) at a typical rat research protocol of 20 mcg per animal per dose yields: 5000 mcg total / 20 mcg per dose = 250 individual doses. For a study using 10 animals dosed twice weekly for 4 weeks (80 total doses), a single 5 mg vial at $50.00 provides ample material with significant remainder. This cost efficiency makes CJC-1295 With DAC relatively accessible for multi-week longitudinal rodent study designs compared to some other long-acting GH secretagogues.

For additional dosage mathematics and concentration-conversion tables, see the peptide dosage calculation guide.

Literature-Reported Research Dose Ranges

Published rodent studies have used subcutaneous doses from 1 mcg/kg (single-dose PK studies) up to 1000 mcg/kg (supra-pharmacological safety evaluations). ^[4] The human phase I clinical studies dosed from 30 to 240 mcg/kg subcutaneously, with 30-60 mcg/kg showing the most favorable signal-to-side-effect ratio in the Ionescu and Teichman studies. These figures are provided as reference values from the primary literature and do not constitute dosing instructions for human use. Researchers designing new preclinical protocols are advised to consult published protocol references and calculate allometric scaling adjustments appropriate to their experimental species.

Side Effects and Safety

Observed Adverse Effects in Research Studies

In the human phase I/II studies by Ionescu and Teichman, the adverse event profile was generally mild. The most commonly reported adverse events across dose groups were: injection-site reactions (erythema, warmth, mild pain) in approximately 30-40% of subjects; transient flushing/facial warmth within 1-2 hours of injection in approximately 15-20%; headache in approximately 10-15%; and dizziness in approximately 5-10%. ^[4][12] No serious adverse events were attributed to the study drug in either trial.

Laboratory safety parameters including fasting blood glucose, HbA1c, cortisol, thyroid function tests, complete blood count, and comprehensive metabolic panel did not show clinically significant group-level changes from baseline. This is consistent with the physiological, somatostatin-gated mechanism of CJC-1295 GH release, which caps the response below pathological GH hypersecretion thresholds. However, individual variability in GH sensitivity means that some research subjects might show greater GH and IGF-1 responses than group means, and these individuals would theoretically carry higher risk for GH-related adverse effects.

GH Excess-Related Adverse Effect Considerations

Exogenous GH or pharmacologically induced GH hypersecretion carries known adverse effect risks including fluid retention (edema), arthralgias, myalgias, carpal tunnel-like paraesthesias, and insulin resistance. ^[14] These effects are dose- and duration-dependent and are associated with GH levels substantially above the physiological range. In the CJC-1295 clinical studies, GH levels, while elevated above pre-study baseline, remained within or near the upper end of physiological pulsatile ranges rather than the supraphysiological levels associated with these complications. Long-term safety at higher doses or in GH-sensitive populations (individuals with pre-existing pituitary pathology, active malignancy, or diabetes) has not been studied.

Cancer Risk Considerations

The in vitro data showing GHRHR expression and proliferative responsiveness in certain cancer cell lines raises a theoretical concern about GHRH analog use in the context of neoplasia. ^[9] No human epidemiological data directly linking CJC-1295 use to cancer incidence exists, and the clinical trial populations were healthy volunteers followed for short durations insufficient to detect any oncological signal. IGF-1 itself is associated in large epidemiological cohort studies with modestly increased risk of certain cancers at the high-normal range of circulating IGF-1. ^[15] Researchers working with cancer models, or extrapolating findings to at-risk populations, should factor this mechanistic consideration into their experimental design and interpretation.

Immunogenicity

With any non-natural peptide, particularly one that forms a covalent adduct with albumin (a self-protein), there is a theoretical risk of immunogenic responses. The clinical studies did not report anti-drug antibody formation, but the trial durations and sample sizes were likely insufficient to detect low-frequency immunogenicity events. In animal model research, particularly in repeated-dose designs, researchers should include immunoglobulin screening as part of the safety monitoring panel if the study duration exceeds four weeks.

How It Compares

CJC-1295 With DAC vs. Modified GRF(1-29) Without DAC

The most frequent point of confusion in the research community is the distinction between CJC-1295 With DAC and Modified GRF(1-29), which is sometimes also called "CJC-1295 without DAC" despite the technical inaccuracy of that name. The backbone amino acid substitutions are similar or identical, but the absence of the DAC linker means the compound is eliminated within 30 minutes of administration and must be dosed frequently to maintain GH axis stimulation. For researchers interested in mimicking a pulsatile GHRH signal, the non-DAC form may actually be more physiologically relevant, as it produces a discrete GH pulse rather than a sustained basal elevation. For studies requiring chronic, sustained GH/IGF-1 elevation with minimal dosing frequency, the DAC form is pharmacologically more practical.

The dosing frequency difference has practical consequences for in vivo rodent studies: modified GRF(1-29) must be dosed daily or twice daily to maintain any ongoing GH axis effect, while CJC-1295 With DAC dosed twice weekly in rodents (or weekly in humans, as per clinical trials) maintains sustained IGF-1 elevation. This reduces the handling stress on experimental animals and simplifies dosing logistics considerably.

CJC-1295 With DAC vs. MK-677

MK-677 (ibutamoren) is an oral, non-peptide ghrelin mimetic that activates the growth hormone secretagogue receptor 1a (GHSR-1a), the ghrelin receptor. Its mechanism is therefore entirely different from CJC-1295: it does not engage GHRHR at all and instead works through the ghrelin pathway. The functional outcome (increased GH and IGF-1 secretion) is similar, and MK-677 has a 24-hour half-life that also enables once-daily dosing. The practical advantage of MK-677 in research settings is its oral bioavailability, eliminating the need for injections. The practical advantage of CJC-1295 With DAC is its even longer once-weekly dosing interval and the availability of a larger Phase I human dataset from the clinical development period. The two compounds are sometimes combined in research protocols to exploit their synergistic action through different receptor pathways, analogous to the clinical observation that GHRH and ghrelin agonists produce supraadditive GH secretion when combined. ^[16]

CJC-1295 With DAC vs. Tesamorelin

Tesamorelin is the approved GHRH analog most pharmacologically similar to CJC-1295 With DAC in terms of mechanism, though not in pharmacokinetics. Tesamorelin is dosed daily via subcutaneous injection and produces robust GH and IGF-1 elevations in HIV-positive patients with lipodystrophy, the approved indication. ^[5] The extensive Phase III safety data for tesamorelin, accumulated over its FDA approval pathway, provides indirect reassurance about the general safety of GHRHR agonism, though it cannot be directly extrapolated to the long-acting CJC-1295 DAC form. Researchers may use tesamorelin data as a mechanistic comparator when interpreting CJC-1295 With DAC findings.

Open Research Questions

Several important mechanistic and pharmacological questions about CJC-1295 With DAC remain incompletely resolved in the published literature.

Question 1: Does the sustained basal GH elevation pattern affect sleep architecture differently from pulsatile GHRH analogs? The nocturnal GH pulse during SWS is a critical regulator of sleep-stage architecture and hypothalamic somatostatin tone. Whether the chronic basal GH elevation from CJC-1295 With DAC enhances, disrupts, or simply augments SWS-associated GH secretion has not been directly studied with polysomnographic endpoints. The mechanistic rationale for both enhancement (via GHRHR sensitization) and disruption (via tonic GH feedback on somatostatin) exist, and the question remains open. ^[11]

Question 2: What are the long-term pituitary safety implications of chronic GHRHR stimulation? Decades of GHRH administration studies in rodents have not produced pituitary hyperplasia or GH-secreting adenoma formation, suggesting that the somatostatin feedback circuit provides adequate protection. However, the available human clinical data for CJC-1295 With DAC extends only to 12 weeks, and the decades-long safety data available for approved pharmaceuticals like tesamorelin involves daily, not weekly, dosing. Long-term intermittent high-dose GHRHR stimulation has not been studied in primates or in multi-year rodent lifetime studies. ^[17]

Question 3: What is the albumin-conjugation efficiency under different physiological conditions? The DAC mechanism depends on the availability of reduced (free thiol) Cys-34 on albumin. In inflammatory conditions, oxidative stress, heavy metal exposure, and certain drug interactions, the proportion of albumin with a free Cys-34 thiol decreases substantially. Conditions like chronic kidney disease, rheumatoid arthritis, and type 2 diabetes are associated with higher proportions of oxidized albumin. Whether the pharmacokinetics of CJC-1295 With DAC are significantly altered in these states, which are common in populations where GH axis research is particularly relevant, has not been directly studied. ^[18]

Question 4: Is there a dose-response relationship for sleep and circadian effects? The circadian rhythm modulation by GH axis peptides is an active research area, but CJC-1295 With DAC specifically has not been the subject of controlled circadian or chronobiology studies. Researchers studying peptide effects on sleep, cognitive function, or metabolic circadian biology would be working in largely unmapped territory with this compound.

Where to Buy

Apollo Peptide Sciences lists the CJC-1295 With DAC 5mg vial at $50.00 under the product identifier cjc-1295-w-dac-2. The vial is sold with a batch-specific CoA available on the product page. Researchers should review the CoA before placing an order and contact the supplier directly if the purity, MS data, or endotoxin values are not disclosed or do not meet the specifications described in the Purity and Verification section above.

For a broader evaluation of GHRH analog and GH secretagogue suppliers across the research peptide market, including criteria for evaluating third-party testing credentials, shipping conditions, and regulatory compliance, see the supplier evaluation guide. Purchasing from a single supplier for an entire study cohort, using the same batch, is advisable to minimize inter-batch variability as a confound in comparative research designs.

FAQ